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Background & aims: Several studies with diabetes-speciﬁc formulas (DSFs) for hyperglycaemic patients
in need of nutritional support have been conducted in non-malnourished patients, mainly comparing
products with varying macronutrient compositions. Here, the effect of a high energy, high protein DSF on
postprandial responses was compared to a product with a similar macronutrient composition in
malnourished or at risk of malnutrition patients with type 2 diabetes.
Methods: In this randomised, double-blind cross-over study, 20 patients were included. After overnight
fasting, patients consumed 200 mL of a DSF or standard supplement (control) (19.6 g protein, 31.2 g
carbohydrates and 10.6 g fat), while continuing their anti-diabetic medication. The formulas differed in
type of carbohydrates and presence of ﬁbre. The postprandial glucose, insulin and glucagon responses
were monitored over 4 h. Data were analysed with a Linear Mixed Model, and results of the modiﬁed ITT
population (n ¼ 19) are shown.
Results: Postprandial glucose response as incremental area under the curve (iAUC), was lower after
consumption of DSF compared with control (489.7 ± 268.5 (mean ± SD) vs 581.3 ± 273.9 mmol/L min,
respectively; p ¼ 0.008). Also, the incremental maximum concentration of glucose (iCmax) was lower for
DSF vs control (3.5 ± 1.4 vs 4.0 ± 1.4 mmol/L; p ¼ 0.007). Postprandial insulin and glucagon levels,
expressed as iAUC or iCmax, were not signiﬁcantly different between groups.
Conclusions: Consumption of a high energy, high protein DSF by older malnourished or at risk of
malnutrition type 2 diabetes patients resulted in a signiﬁcantly lower glucose response compared to
control. These data suggest that the use of a DSF is preferred for patients with diabetes in need of
nutritional support.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Malnutrition is highly prevalent among older patients with type
2 diabetes in a hospital or geriatric care setting [1,2] and is an
important predictor for longer hospital stays and poorer clinical
outcomes [1,3]. Nutritional management is an integral part of dia-
betes care, but additional considerations apply for older adults withAdvanced Medical Nutrition,
Vogel-van den Bosch).
Ltd. This is an open access article udiabetes. Maintaining a proper nutritional status can be quite
challenging due to acute disease, functional status or severe co-
morbidities [4]. If an individual's nutritional needs cannot be
reached with usual dietary intake or meal modiﬁcations, other
interventions are encouraged such as the use of oral nutritional
supplements between meals [4].
Oral nutritional supplements should provide sufﬁcient macro
and micro-nutrients including energy, protein, vitamins and min-
erals to reduce the risk of malnutrition [5]. However, many stan-
dard oral nutritional supplements may result in high postprandial
glucose responses in patients with type 2 diabetes. On the shortnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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increased urinary excretion of glucose and thus energy, as well as
an increased risk of infections and urinary incontinence. In hospi-
talized patients, hyperglycemia is associated with increased
morbidity, mortality and longer hospital stay [6]. Preventing high
blood glucose excursions, thus, seems a valid target to improve the
patients' quality of life and save health care resources associated
with poor outcome.
Nutritional requirements of malnourished patients with dia-
betes could be met with specially designed diabetes formulas. In
the past, diabetes speciﬁc formulas (DSFs) contained ingredients
such as high levels of fructose and/-or a large amount of mono-
unsaturated fatty acids, aimed to limit postprandial glucose ex-
cursions as much as possible. It was demonstrated that the DSFs
compared with standard formulas improved blood glucose levels
[7]. However, the levels of fructose and contribution of >35% energy
of fat in these formulas were still of concern, due to potential
detrimental effects on lipid metabolism and a low compliance with
the nutritional guidelines [8,9]. Currently, there are commercially
available DSFs that comply with a lower energy % of fat, andmost of
them contain a slow digestible form of carbohydrates [10].
However, no studies have been performed with these supple-
ments in the target population of these products: diabetes patients
withmalnutrition or at risk of malnutrition. In addition, most of the
comparisons between DSFs and standard nutritional supplements
used different levels of macronutrients contributing to total energy
content [11], these could differentially modulate postprandial
control [12] and limits the conclusion on a clear mechanism of
action. The aim of this study was, therefore, to examine in
malnourished or at risk of malnutrition type 2 diabetes patients
whether a DSF (high energy, high protein and part of the carbo-
hydrate fraction including isomaltulose as a slow release sugar
source) would result in an attenuated postprandial glucose
response compared to a standard nutritional supplement with
similar energy content and similar percentages of carbohydrate, fat
and protein macronutrients contributing to the total energy. In
addition, during an open label study extension, glycaemic re-
sponses were determined after oral intake of a full serving
compared to two half servings of the diabetes speciﬁc formula.
2. Materials and methods
2.1. Patients
Patients were recruited in hospitals, rehabilitation centres and/
or nursing homes. Inclusion criteria were; patients aged 18 years
with the diagnosis of type 2 diabetes for at least six months prior to
study entry and be on stable anti-hyperglycaemic therapy (oral
medication and/or insulin) for at least 1 month prior to study entry.
Patients should also be malnourished or at risk of malnutrition
according to the presence of one or more of the following criteria
that were partly derived from the French clinical practice guide-
lines on nutritional support strategy for protein-energy malnutri-
tion in the elderly [13] and the use of the Mini Nutritional
Assessment®-Short Form (MNA®-SF) [14]: 1) 5% involuntary
weight loss in the last month, or 2)10% involuntary weight loss in
the last 6 months, or 3) Serum albumin <35 g/L, or 4) Age  70 yrs
and body mass index (BMI) < 21.0 kg/m2, or 5) Age < 70 yrs and
BMI < 18.5 kg/m2, or Age  65 yrs and MNA®-SF score  11. In
addition, MNA®-SF score was recorded for all included patients.
Patients were excluded if: 1) they had any gastrointestinal dis-
ease that interferes with bowel function and nutritional intake,
heart failure (New York Heart Association (NYHA) class IV), kidney
disease (Chronic Kidney Disease (CKD)  stage 4), hepatic disease
(transaminases > 5 times upper limit of normal), severe anaemia(haemoglobin <8 g/dl or 5 mmol/L), 2) their current condition or
treatment interferes with stable glucose metabolism, such as un-
controlled thyroid disease, post operation, pregnancy, or having
major infections, 3) When the diet pattern includes: a ﬁbre free
diet, intolerance of any of the ingredients in the study products,
alcohol intake of >21 units and >14 units for men and women,
respectively, 4) they had difﬁculties swallowing the study products
or are dependent on parenteral or tube feeding, 5) in case the in-
vestigators are uncertain about the willingness or ability of the
subject to comply with the protocol requirements, or when the
patients are already participating in another study. Throughout the
study, the patients were requested to keep medication constant
and to maintain their normal dietary habits whenever possible.
All patients gave written informed consent before screening
and were aware that they could stop the study at any time they
desired. The study protocol was approved by Comite de protection
des personnes e Ho^pital Ho^tel-Dieu; 1, place du Parvis-de-Notre-
Dame, 75181 Paris Cedex, France and the study was registered at
http://www.trialregister.nl/trialreg/admin/rctview.asp?TC¼3734
as NTR3734.
2.2. Study design
The study had a randomised, double blind, crossover design
with an open label extension day. For investigation of the primary
objective, patients had to complete two study days in randomised
order, receiving either the diabetes-speciﬁc formula (DSF) on the
ﬁrst study day (visit 1) and the standard nutritional supplement
(control) on the second study day (visit 2) or vice versa. The wash-
out period between the study days was 3e14 days. After a second
wash-out period, the patients could complete an open label third
study day (visit 3) to investigate the effect of serving size. On the
morning of each study day, the patients arrived at the research
centre after an overnight fast and no changes were made in dia-
betes medicine prescription or treatment protocol. Fifteen minutes
before the ﬁrst blood samples were taken, an intravenous cannula
was placed in a forearm vein to allow repeated blood sample
collection for 4 h. Subjects received the study product at t ¼ 0 min
and had to consume it within 10 min. Venous blood samples were
drawn at two time-points before (t 10 and t 5 min) and at 8
time-points after starting consumption of the study product (t 15, t
30, t 45, t 60, t 90, t 120, t 180, and t 240 min) to measure the 4-
h postprandial blood glucose, insulin and glucagon responses.
During these measurements, subjects were instructed to sit or lie
down quietly, e.g. reading a book or watching television. Thereafter,
the cannulawas removed, and a lunchwas provided. On visit days 1
and 2, fasting and postprandial (t ¼ 30, 60, 120, 240 min) C-peptide
was also determined. On the ﬁrst study day, fasting blood samples
were used for the analyses of HbA1c, serum albumin, triglycerides,
total cholesterol, LDL-cholesterol and HDL-cholesterol. During the
open-label extension study day, the patients consumed the DSF in
serving sizes of 100 mL (2  100 mL), of which the ﬁrst serving at
breakfast (t 0) and the second serving 2 h later (during the post-
prandial measurements at t 120).
2.3. Study product(s)
The DSF used was Fortimel DiaCare (Nutricia N.V, Zoetermeer,
the Netherlands), which is a 200 mL high-energy (1.51 kcal/mL),
high-protein, ready to drink oral nutritional supplement (ONS),
enriched with soluble ﬁbre and containing speciﬁc carbohydrates
(Table 1). As control, Fortimel Extra (Nutricia N.V., Zoetermeer, The
Netherlands) was used, which is also a high-energy (1.50 kcal/mL),
high-protein, ready to drink ONS with a similar macronutrient
composition as the DSF except for the ﬁbre content and the
Table 1
Energy content and macronutrient composition on the study products.
DSF (100 mL) Control (100 mL)
Energy (kcal) 151 150
Protein g (En%) 9.8 (26) 9.8 (26.2)
- Casein g 7.84 7.84
- Whey g 1.96 1.96
Carbohydrate g (En%) 15.6 (41.2) 15.6 (41.5)
- Glucose/Maltose g 0.7 0.6
- Lactose g 3.4 3.1
- Isomaltulose g 5.6 e
- Sucrose e 1.3
- Polysaccharides 5.5 10.4
- Other 0.4 0.3
Fat g (En%) 5.3 (31.9) 5.3 (32.2)
- Saturated g 0.64 0.63
- MUFA g 3.17 3.17
- PUFA g 1.53 1.53
Fibre g (En%) 0.7 (0.9) e
DSF; diabetes speciﬁc formula, Control; Standard Nutritional Supplement, MUFA;
mono unsaturated fatty acid, PUFA; poly unsaturated fatty acid.
Table 2
Laboratory blood parameters describing baseline patient characteristics
(Mean ± SD, n ¼ 19).
Total (n ¼ 19)
Triglycerides (mmol/L) 2.12 ± 1.27
Cholesterol (mmol/L) 5.16 ± 1.69
LDL Cholesterol (mmol/L) 2.95 ± 1.15
HDL Cholesterol (mmol/L) 0.96 ± 0.24
Albumin (g/L) 35.58 ± 2.63
Haemoglobin A1C (mmol/mol)a 54.55 ± 9.26
a n ¼ 16.
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vitamins, minerals and trace elements in accordance with the
regulations for Food for Special Medical Purposes (FSMP) (1999/21/
EC).
2.4. Blood analysis and calculations
All blood samples were analysed by a certiﬁed laboratory
(Reinier de Graaf Hospital, Department of Clinical Chemistry, Delft,
The Netherlands). Blood HbA1c was determined by HPLC (Tosoh
Diagnostics, Tessenderlo, Belgium), plasma glucagon was deter-
mined using a radio immune assay (Siemens Healthcare Di-
agnostics, Breda, The Netherlands), serum insulin and C-peptide
were studied via immunoluminometric assays (Siemens Healthcare
Diagnostics, Breda, TheNetherlands) and serumglucose, TAG, total-,
LDL- and HDL-cholesterol were analysed using commercial kits
(Abbott Diagnostics, Olst, The Netherlands).
Plasma glucose, insulin, glucagon and C-peptide responses were
calculated for the individual time curves as positive iAUC above
baseline levels (t ¼ 0 min) according to the methodology described
by Brouns et al. [15]. For plasma glucose, insulin and glucagon, also
the Cmax and iCmax were calculated as the average of the indi-
vidual Cmax and iCmax values. Cmax is the postprandial peak
glucose concentration and iCmax the postprandial delta peak
glucose concentration (postprandial peak glucose concentration
minus the baseline glucose concentration).
2.5. Statistical analyses
Before initiation of the study, a sample size of 10 patients per
group was calculated (Proc Power, SAS Enterprise Guide version
4.3) to be sufﬁcient to detect a 30% reduction in iAUC between the
test and the control product, with a power of 80% and a signiﬁcance
level (a) of 0.05, assuming an iAUC0-4h glucose of 666 mmol/L min
in the control group and a standard deviation of 290 [16]. Com-
parisons between the DSF and control groupswere analysed using a
PROC MIXED model with a compound symmetry covariance
structure; and with period and product as ﬁxed factors and subject
number as repeated factor. Underlying assumptions for the appli-
cation of mixed models were checked and if assumptions were not
met, data transformations and/or non-parametric test (paired-
sample Wilcoxon signed rank test) were used to assess the statis-
tical differences between the treatments. Comparisons between
the full DSF serving and 2 halve servings of DSFwere analysed usinga paired t-test. SAS Enterprise Guide 4.3 for Windows (SAS Insti-
tute) software was used for all statistical analyses. In this paper, the
results of the modiﬁed ITT population are shown, which consisted
of all randomized subjects (n ¼ 20) minus one subject who had
violated one exclusion criterion. After unblinding, it became clear
that this subject had violated the exclusion criterium: ‘Concurrent
condition/treatment that interfereswith stable glucose metabolism
(i.e. immediately post-operative)’. For the safety analysis, the all
subjects randomized population (n ¼ 20) was used. Statistical sig-
niﬁcance was deﬁned as a 2-tailed p < 0.05 and data in text and
tables are expressed as means ± SEMs, unless otherwise indicated.
3. Results
3.1. Patient enrolment
In total, 21 patients were screened, of which 20 patients were
randomized at visit 1. These patients were staying in a rehabilita-
tion centre (n ¼ 6), a nursing home (n ¼ 7) and a long term-care
home (n ¼ 7). The one patient not randomized died just before
visit 1. Twenty subjects completed the study. The open-label study
extensionwas started and ﬁnalized by 17 patients. Of the 3 patients
in the main study that did not start the open-label study, one pa-
tient diet shortly after the last visit of the main study and 2 patients
did not attend the experimental day of the open label study due to
practical reasons.
3.2. Patient characteristics
Themean age of the patients (10male/9 female)was 82.3± 6.5 y,
weight 76.5 ± 18.5 kg, height 1.60 ± 0.08 m, BMI 29.8 ± 7.0 kg/m2,
waist circumference 107.8 ± 17.2 cm, diabetes duration 256 ± 203
months (means ± SD). Baseline laboratory parameters describing
patient characteristics (HbA1c, HDL, LDL, Albumin, Chol, TAG) are
shown inTable 2. Of the 19 patients,17were on insulin alone (9 basal
insulin and 8 premix insulin), 2 were on oral medication (DPP IV
inhibitor and sulfonylurea, DPP IV inhibitor and metformin). Seven
patients were malnourished or at risk of malnutrition based on a
serum albumin level below 35 g/L. Among these 7 patients older
than 65 y, 2 had a concomitant C reactive protein concentration
higher than 20 mg/L and according to MNA®-SF, 3 were malnour-
ished and 4 were at risk of malnutrition. The other patients were
included based on an MNA®-SF score of 11 or lower and older than
65 y and the last one was older than 70 with a BMI lower than 21
with an MNA®-SF lower than 11.
3.3. Glucose responses
Plasma glucose concentrations at each time point after the oral
intake of the different supplements are shown in Fig. 1A. The iAUC
was signiﬁcantly lower after intake of the DSF compared with the
control (p ¼ 0.008) (Fig. 1B). Maximal incremental concentration of
Fig. 1. Postprandial response of glucose (A) and postprandial incremental area under
the curve of glucose (B) after consumption of a high energy, high protein diabetes
speciﬁc formula (DSF), an isocaloric control supplement or two half servings of the
diabetes speciﬁc formula (means ± SEM), *p < 0.01 comparing control vs DSF,
**p < 0.05 comparing DSF vs 2 half servings of DSF.
Fig. 2. Postprandial response of insulin (A) and postprandial incremental area under
the curve of insulin (B) after consumption of a high energy, high protein diabetes
speciﬁc formula (DSF), an isocaloric control supplement or two half servings of the
diabetes speciﬁc formula (means ± SEM), **p < 0.05 comparing DSF vs 2 half servings
of DSF.
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compared to control (p ¼ 0.007), but the difference in Cmax of
glucose between the formulas did not reach statistical signiﬁcance
(p ¼ 0.107) (Table 3). Comparison of the oral intake of two half
servings of DSF within 240 min with one full serving in a similar
time span showed a signiﬁcantly lower iAUC in the two half serving
condition (p < 0.05) (Fig. 1B). No differences between both treat-
ments were shown on glucose Cmax (p ¼ 0.9) or glucose iCmax
(p ¼ 0.16) (Table 3).
3.4. Insulin responses
Postprandial plasma insulin concentrations are shown in Fig. 2A.
The iAUC was not signiﬁcantly different after consumption of the
DSF compared with the control (p ¼ 0.185) (Fig. 2B). Maximal in-
cremental concentration of insulin trended to be higher in the DSFTable 3
Maximal (CMax) and incremental maximal (iCMax) glucose, insulin and glucagon respon
Glucose Insulin
Cmax (mmol/L) iCmax (mmol/L) Cmax (mU
Control 11.3 ± 0.5 4 ± 0.3 48 ± 7.2
DSF 10.8 ± 0.5 3.5 ± 0.3* 56.8 ± 10
2* half DSF 10.6 ± 0.8 3 ± 0.4 49 ± 7.9
Control and DSF n ¼ 19, 2* half DSF n ¼ 17, *p < 0.01 comparing control vs DSF, **p < 0vs the control (p ¼ 0.07), but was not signiﬁcantly different for
insulin Cmax (0.124) (Table 3).
Consumption of twice half a serving of DSF compared with one
full serving showed a signiﬁcantly lower insulin iAUC (p < 0.05)
(Fig. 2B). Maximal incremental insulin concentrationwas also lower
after consumption of 2 half servings compared to a full servingof the
DSF (p< 0.05) (Table 3). Absolute postprandial insulin Cmaxwas not
signiﬁcantly different between both conditions (Table 3).3.5. Glucagon and C-peptide responses
Plasma glucagon concentrations after oral intake of the different
supplements are shown in Fig. 3A. Overall postprandial glucagon
iAUC was not signiﬁcantly different between the DSF and theses after consumption of the test products (mean ± SEM).
Glucagon
/L) iCmax (mU/L) Cmax (pmol/L) iCmax (pmol/L)
33.8 ± 5.0 31.5 ± 3.6 15.3 ± 3.5
.6 43.2 ± 8.5 31.8 ± 4.2 15.9 ± 3.8
27.1 ± 3.7** 25.8 ± 2.1 10.1 ± 1.9
.05 comparing DSF vs 2* half DSF (DSF: diabetes speciﬁc formula).
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between the DSF and the control for Cmax of glucagon (p¼ 0.96) or
iCmax of glucagon (p ¼ 0.73) (Table 3). Oral intake of two half
servings of DSF showed a trend for a lower glucagon iAUC
compared to a full serving of DSF (p ¼ 0.076, Fig. 3B). No signiﬁcant
changes were observed between the full and 2 half servings for
Cmax of glucagon (p ¼ 0.21) and iCmax of glucagon (p ¼ 0.15)
(Table 3).
There was no statistically signiﬁcant difference in iAUC of C-
peptide after theDSF comparedwith the control (206.60±31.3nmol/
L*min vs. 197.06 ± 29.4 nmol/L*min, resp., p ¼ 0.416).
3.6. Compliance and safety
All patients consumed the DSF or control within 10 min and
were reported to be 100% compliant for each dosing during intake.
In total, 5 persons reported 10 adverse events during the course of
the study. One patient had 2 serious adverse events (peripheral
ischaemia). This patient was excluded from the ITT due to violation
of an exclusion criterion. Of the remaining 4 patients, 3 reported
AEs in the period the test product was studied and 1 patient when
the control product was studied. None of the events were consid-
ered related to the intake of the study products. These reported
events had the body system classiﬁcation: nervous system disorder
(n ¼ 2), infections and infestations (n ¼ 1), gastrointestinal disor-
ders (n ¼ 2) and injury (n ¼ 3), which are consistent with theFig. 3. Postprandial response of glucagon (A) and postprandial incremental area under
the curve of glucagon (B) after consumption of a high energy, high protein diabetes
speciﬁc formula (DSF), an isocaloric control supplement or two half servings of the
diabetes speciﬁc formula (means ± SEM).polypathologic nature of older adult malnourished or at risk of
malnutrition patients with diabetes type II in a long term care unit,
and, therefore, did not qualify as a safety signal.
4. Discussion
This study showed that consumption of a high energy, high
protein, diabetes speciﬁc formula (DSF) resulted in a lower post-
prandial glucose response compared to a standard nutritional
supplement (control) with the same macronutrient energy
composition in older malnourished or at risk of malnutrition type 2
diabetes patients.
Other recent studies have described the beneﬁcial effects of a
diabetes speciﬁc oral supplement on postprandial glucose or longer
term glucose control compared to other formulas or meals
[10,11,17e21]. For instance, Garcia-Rodriguez et al. [11] showed an
improved postprandial glucose response comparing a novel DSF
against twoother commercially availableDSFs due to the addition of
slowly digestible carbohydrate resistant starch type IV as part of the
carbohydrates and 2% ﬁbres from inulin and cellulose. Although
differences in caloric content, amount and type of protein and
amount and type of fat between the different DSFs were not taken
into account separately, it is likely that the entire combination
contributed to the observed effects. In contrast, Buranapin et al. [19]
demonstrated a signiﬁcantly lower postprandial glucose response
after DSF intake compared to standard ONS with matched energy
content and macronutrient percentages. This DSF was a modiﬁed
standard formula with multiple substitutions in all the macronu-
trients. Since the individual adjustments of the composition were
not studied in isolation probably all adjustments together contrib-
uted to the beneﬁcial effect on postprandial glucose level. Unfor-
tunately, no insulin or glucagon responses were measured, which
may have provided additional insights in the macronutrient
induced changes in postprandial metabolism. A modiﬁed protein
composition could, for example, impact pancreas insulin output or
glucagon secretion increasing liver glycolysis.
In this study, we speciﬁcally aimed to match for caloric content,
type and energy % of protein and type and energy % of fat
comparing control and a DSF. We substituted part of the carbohy-
drates (maltodextrin) for isomaltulose, which resulted in an
attenuated postprandial glucose response andwithout an excessive
insulin or glucagon response. Isomaltulose (palatinose) is a disac-
charide produced by enzymatic conversion of the 1,2-glycosidic
linkage between glucose and fructose of sucrose to a a-1,6-linked
glucose and fructose [22]. Therefore, isomaltulose is slowly diges-
ted, and the resulting glucose and fructose are released at a slow
pace creating an excellent source to manage postprandial glucose
responses. Isomaltulose consumed in a drink with a meal has
indeed been shown to attenuate the postprandial rise in glucose
levels compared to sucrose in impaired glucose-tolerant subjects
[23]. Furthermore, head to head comparison between sucrose and
isomaltulose on postprandial glucose responses during a eugly-
caemicehyperinsulinemic clamp in type 2 diabetes patients
showed a slower absorption of isomaltulose, which resulted in
lower levels of glucose, insulin, glucagon and c-peptide [24].
The DSF also provided galacto-oligosaccharides (GOS) as non-
digestible soluble ﬁbres, which contributed less than 1% to total
energy intake and thus not likely to be effective on glucose control.
Consumption of 2.5 g per day has been shown to convey a prebiotic
effect stimulating growth of the intestinal Biﬁdobacteria [25].
Furthermore, several other proposed beneﬁts of GOS include:
protection against infections, increased mineral absorption and a
reduction in toxigenic microbial metabolism [26]. In this acute
study, no side effects or gastrointestinal complaints were observed
after consumption of both formulas. Whether increased and longer
H. Laksir et al. / Clinical Nutrition 37 (2018) 2084e2090 2089term consumption of the formula would indeed deliver prebiotic
effects and additional health beneﬁts remains subject of future
study.
Protein energy malnutrition can result in many detrimental
health conditions, such as: muscle wasting, poor wound healing,
impaired immune response and inactivity [27]. Therefore, this DSF
was designed to provide high energy and a high protein content, in
line with the nutritional support strategy for protein-energy
malnourished older adults from the French Nutrition and Health
Program (HAS: Haute Autorite de Sante) [13]. Protein content could
be considered relatively high with 26 energy % per serving for pa-
tients with diabetes; nutritional guidelines generally recommend
20% of energy be contributed by protein on a daily basis [28,29].
Nevertheless, it should be taken into account that most malnour-
ished or at risk of malnutrition (older adult) patients have an under
consumption of not only energy but also protein, which is the un-
derlying motivation to prescribe these patients the use of medical
nutritional supplements and ﬁll this gap in daily protein intake.
Recently, the American Diabetes Association (ADA) communicated
that the evidence for a general protein intake recommendation for
diabetes patients was inconclusive [9]. Therefore, current protein
intake recommendations for diabetes patients are prescribed on the
basis of the individual's nutritional status and co-morbid condition.
For example, it has been shown that diabetes is associated with a
faster loss of muscle strength and a lower leg muscle quality
compared to subjects with normal glycaemic control [30]. This may
indicate that increased high quality dietary protein intake may be
beneﬁcial [27,31]. On the other hand, caution is necessary when
prescribing the DSF for malnourished diabetes patients with an
impaired kidney function, due to the presumed link between high
protein intake and the increased risk for kidney failure [32].
An alternative strategy to lower the burden of a medical nutri-
tion supplement on postprandial glucose and reduce glycaemic
variability, while still supplying adequate calories and protein,
might be the consumption of smaller dosages of the diabetes spe-
ciﬁc formula. Consecutive consumption of 2 half servings compared
to the full serving resulted in a lower total postprandial glucose
response (iAUC). Total insulin response was also signiﬁcantly lower
after the 2 half servings of the DSF compared with the full serving,
while in total the same amount of nutrients were consumed. These
results provide a solution for the individual nutritional needs of the
malnourished patient with diabetes regarding energy and protein
in the context of a low or high insulin and glucagon response.
A limitation of the study explaining the variation in the reported
outcomes could be the patients' diverse treatment strategies.
However, in general, this does reﬂect the heterogeneity of the pa-
tients in real life. Furthermore, the sample size of the current study
is small, but due to its cross-over design and the measurement of
4 h instead of the standard 2 h postprandial response, a good
representation of the effects of the consumption in daily life is
obtained. Whether the beneﬁcial effects on glycaemic control
persist after longer term use could be the subject of future studies.
Although, a previous study with a DSF already demonstrated that
an acute attenuation of the postprandial glucose control in a T2D
patient population was maintained after 4 weeks use of two serv-
ings a day [20].
5. Conclusion
Consumption of a high-energy, high-protein, ﬁbre and low
glycaemic index carbohydrate enriched diabetes speciﬁc formula
resulted in a lower postprandial blood glucose response compared
with an iso-caloric standard high-energy high-protein oral nutri-
tional supplement in older malnourished or at risk of malnutrition
type 2 diabetes patients. These data suggest that this DSF in full or 2half servings is preferred for patients with diabetes in need of
personalized nutritional support.
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